Report Detail

Medical Devices & Consumables Global Gestational Trophoblastic Disease Market Growth (Status and Outlook) 2022-2028

  • RnM4495439
  • |
  • 23 November, 2022
  • |
  • Global
  • |
  • 101 Pages
  • |
  • LPI(LP Information)
  • |
  • Medical Devices & Consumables

Gestational trophoblastic disease (GTD) is a group of rare diseases in which abnormal trophoblast cells grow inside the uterus after conception. In gestational trophoblastic disease (GTD), a tumor develops inside the uterus from tissue that forms after conception (the joining of sperm and egg).

The global market for Gestational Trophoblastic Disease is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC Gestational Trophoblastic Disease market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States Gestational Trophoblastic Disease market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe Gestational Trophoblastic Disease market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China Gestational Trophoblastic Disease market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key Gestational Trophoblastic Disease players cover Bristol Myers Squibb, Antares Pharma, Novartis AG, Accord Healthcare Limited and Eli Lilly and Company, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

Report Coverage
This latest report provides a deep insight into the global Gestational Trophoblastic Disease market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global Gestational Trophoblastic Disease market, with both quantitative and qualitative data, to help readers understand how the Gestational Trophoblastic Disease market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions.

Market Segmentation:
The study segments the Gestational Trophoblastic Disease market and forecasts the market size by Type (Chemotherapy, Surgery and Radiation Therapy), by Application (Hospitals, Clinics, Cancer Research Institutes and Others), and region (APAC, Americas, Europe, and Middle East & Africa).

Segmentation by type
Chemotherapy
Surgery
Radiation Therapy
Others

Segmentation by application
Hospitals
Clinics
Cancer Research Institutes
Others

Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Major companies covered
Bristol Myers Squibb
Antares Pharma
Novartis AG
Accord Healthcare Limited
Eli Lilly and Company
Sanofi
Bayer AG
Amgen
Merck KGaA
Teva Pharmaceuticals
B.P Pharma

Chapter Introduction
Chapter 1: Scope of Gestational Trophoblastic Disease, Research Methodology, etc.
Chapter 2: Executive Summary, global Gestational Trophoblastic Disease market size and CAGR, Gestational Trophoblastic Disease market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Gestational Trophoblastic Disease revenue, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Gestational Trophoblastic Disease revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, revenue segment by country, by type, and application.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Gestational Trophoblastic Disease market size forecast by region, by country, by type, and application
Chapter 13: Comprehensive company profiles of the leading players, including Bristol Myers Squibb, Antares Pharma, Novartis AG, Accord Healthcare Limited, Eli Lilly and Company, Sanofi, Bayer AG, Amgen and Merck KGaA, etc.
Chapter 14: Research Findings and Conclusion


1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global Gestational Trophoblastic Disease Market Size 2017-2028
    • 2.1.2 Gestational Trophoblastic Disease Market Size CAGR by Region 2017 VS 2022 VS 2028
  • 2.2 Gestational Trophoblastic Disease Segment by Type
    • 2.2.1 Chemotherapy
    • 2.2.2 Surgery
    • 2.2.3 Radiation Therapy
    • 2.2.4 Others
  • 2.3 Gestational Trophoblastic Disease Market Size by Type
    • 2.3.1 Gestational Trophoblastic Disease Market Size CAGR by Type (2017 VS 2022 VS 2028)
    • 2.3.2 Global Gestational Trophoblastic Disease Market Size Market Share by Type (2017-2022)
  • 2.4 Gestational Trophoblastic Disease Segment by Application
    • 2.4.1 Hospitals
    • 2.4.2 Clinics
    • 2.4.3 Cancer Research Institutes
    • 2.4.4 Others
  • 2.5 Gestational Trophoblastic Disease Market Size by Application
    • 2.5.1 Gestational Trophoblastic Disease Market Size CAGR by Application (2017 VS 2022 VS 2028)
    • 2.5.2 Global Gestational Trophoblastic Disease Market Size Market Share by Application (2017-2022)

3 Gestational Trophoblastic Disease Market Size by Player

  • 3.1 Gestational Trophoblastic Disease Market Size Market Share by Players
    • 3.1.1 Global Gestational Trophoblastic Disease Revenue by Players (2020-2022)
    • 3.1.2 Global Gestational Trophoblastic Disease Revenue Market Share by Players (2020-2022)
  • 3.2 Global Gestational Trophoblastic Disease Key Players Head office and Products Offered
  • 3.3 Market Concentration Rate Analysis
    • 3.3.1 Competition Landscape Analysis
    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
  • 3.4 New Products and Potential Entrants
  • 3.5 Mergers & Acquisitions, Expansion

4 Gestational Trophoblastic Disease by Regions

  • 4.1 Gestational Trophoblastic Disease Market Size by Regions (2017-2022)
  • 4.2 Americas Gestational Trophoblastic Disease Market Size Growth (2017-2022)
  • 4.3 APAC Gestational Trophoblastic Disease Market Size Growth (2017-2022)
  • 4.4 Europe Gestational Trophoblastic Disease Market Size Growth (2017-2022)
  • 4.5 Middle East & Africa Gestational Trophoblastic Disease Market Size Growth (2017-2022)

5 Americas

  • 5.1 Americas Gestational Trophoblastic Disease Market Size by Country (2017-2022)
  • 5.2 Americas Gestational Trophoblastic Disease Market Size by Type (2017-2022)
  • 5.3 Americas Gestational Trophoblastic Disease Market Size by Application (2017-2022)
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC Gestational Trophoblastic Disease Market Size by Region (2017-2022)
  • 6.2 APAC Gestational Trophoblastic Disease Market Size by Type (2017-2022)
  • 6.3 APAC Gestational Trophoblastic Disease Market Size by Application (2017-2022)
  • 6.4 China
  • 6.5 Japan
  • 6.6 Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia

7 Europe

  • 7.1 Europe Gestational Trophoblastic Disease by Country (2017-2022)
  • 7.2 Europe Gestational Trophoblastic Disease Market Size by Type (2017-2022)
  • 7.3 Europe Gestational Trophoblastic Disease Market Size by Application (2017-2022)
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa Gestational Trophoblastic Disease by Region (2017-2022)
  • 8.2 Middle East & Africa Gestational Trophoblastic Disease Market Size by Type (2017-2022)
  • 8.3 Middle East & Africa Gestational Trophoblastic Disease Market Size by Application (2017-2022)
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends

10 Global Gestational Trophoblastic Disease Market Forecast

  • 10.1 Global Gestational Trophoblastic Disease Forecast by Regions (2023-2028)
    • 10.1.1 Global Gestational Trophoblastic Disease Forecast by Regions (2023-2028)
    • 10.1.2 Americas Gestational Trophoblastic Disease Forecast
    • 10.1.3 APAC Gestational Trophoblastic Disease Forecast
    • 10.1.4 Europe Gestational Trophoblastic Disease Forecast
    • 10.1.5 Middle East & Africa Gestational Trophoblastic Disease Forecast
  • 10.2 Americas Gestational Trophoblastic Disease Forecast by Country (2023-2028)
    • 10.2.1 United States Gestational Trophoblastic Disease Market Forecast
    • 10.2.2 Canada Gestational Trophoblastic Disease Market Forecast
    • 10.2.3 Mexico Gestational Trophoblastic Disease Market Forecast
    • 10.2.4 Brazil Gestational Trophoblastic Disease Market Forecast
  • 10.3 APAC Gestational Trophoblastic Disease Forecast by Region (2023-2028)
    • 10.3.1 China Gestational Trophoblastic Disease Market Forecast
    • 10.3.2 Japan Gestational Trophoblastic Disease Market Forecast
    • 10.3.3 Korea Gestational Trophoblastic Disease Market Forecast
    • 10.3.4 Southeast Asia Gestational Trophoblastic Disease Market Forecast
    • 10.3.5 India Gestational Trophoblastic Disease Market Forecast
    • 10.3.6 Australia Gestational Trophoblastic Disease Market Forecast
  • 10.4 Europe Gestational Trophoblastic Disease Forecast by Country (2023-2028)
    • 10.4.1 Germany Gestational Trophoblastic Disease Market Forecast
    • 10.4.2 France Gestational Trophoblastic Disease Market Forecast
    • 10.4.3 UK Gestational Trophoblastic Disease Market Forecast
    • 10.4.4 Italy Gestational Trophoblastic Disease Market Forecast
    • 10.4.5 Russia Gestational Trophoblastic Disease Market Forecast
  • 10.5 Middle East & Africa Gestational Trophoblastic Disease Forecast by Region (2023-2028)
    • 10.5.1 Egypt Gestational Trophoblastic Disease Market Forecast
    • 10.5.2 South Africa Gestational Trophoblastic Disease Market Forecast
    • 10.5.3 Israel Gestational Trophoblastic Disease Market Forecast
    • 10.5.4 Turkey Gestational Trophoblastic Disease Market Forecast
    • 10.5.5 GCC Countries Gestational Trophoblastic Disease Market Forecast
  • 10.6 Global Gestational Trophoblastic Disease Forecast by Type (2023-2028)
  • 10.7 Global Gestational Trophoblastic Disease Forecast by Application (2023-2028)

11 Key Players Analysis

  • 11.1 Bristol Myers Squibb
    • 11.1.1 Bristol Myers Squibb Company Information
    • 11.1.2 Bristol Myers Squibb Gestational Trophoblastic Disease Product Offered
    • 11.1.3 Bristol Myers Squibb Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2020-2022)
    • 11.1.4 Bristol Myers Squibb Main Business Overview
    • 11.1.5 Bristol Myers Squibb Latest Developments
  • 11.2 Antares Pharma
    • 11.2.1 Antares Pharma Company Information
    • 11.2.2 Antares Pharma Gestational Trophoblastic Disease Product Offered
    • 11.2.3 Antares Pharma Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2020-2022)
    • 11.2.4 Antares Pharma Main Business Overview
    • 11.2.5 Antares Pharma Latest Developments
  • 11.3 Novartis AG
    • 11.3.1 Novartis AG Company Information
    • 11.3.2 Novartis AG Gestational Trophoblastic Disease Product Offered
    • 11.3.3 Novartis AG Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2020-2022)
    • 11.3.4 Novartis AG Main Business Overview
    • 11.3.5 Novartis AG Latest Developments
  • 11.4 Accord Healthcare Limited
    • 11.4.1 Accord Healthcare Limited Company Information
    • 11.4.2 Accord Healthcare Limited Gestational Trophoblastic Disease Product Offered
    • 11.4.3 Accord Healthcare Limited Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2020-2022)
    • 11.4.4 Accord Healthcare Limited Main Business Overview
    • 11.4.5 Accord Healthcare Limited Latest Developments
  • 11.5 Eli Lilly and Company
    • 11.5.1 Eli Lilly and Company Company Information
    • 11.5.2 Eli Lilly and Company Gestational Trophoblastic Disease Product Offered
    • 11.5.3 Eli Lilly and Company Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2020-2022)
    • 11.5.4 Eli Lilly and Company Main Business Overview
    • 11.5.5 Eli Lilly and Company Latest Developments
  • 11.6 Sanofi
    • 11.6.1 Sanofi Company Information
    • 11.6.2 Sanofi Gestational Trophoblastic Disease Product Offered
    • 11.6.3 Sanofi Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2020-2022)
    • 11.6.4 Sanofi Main Business Overview
    • 11.6.5 Sanofi Latest Developments
  • 11.7 Bayer AG
    • 11.7.1 Bayer AG Company Information
    • 11.7.2 Bayer AG Gestational Trophoblastic Disease Product Offered
    • 11.7.3 Bayer AG Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2020-2022)
    • 11.7.4 Bayer AG Main Business Overview
    • 11.7.5 Bayer AG Latest Developments
  • 11.8 Amgen
    • 11.8.1 Amgen Company Information
    • 11.8.2 Amgen Gestational Trophoblastic Disease Product Offered
    • 11.8.3 Amgen Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2020-2022)
    • 11.8.4 Amgen Main Business Overview
    • 11.8.5 Amgen Latest Developments
  • 11.9 Merck KGaA
    • 11.9.1 Merck KGaA Company Information
    • 11.9.2 Merck KGaA Gestational Trophoblastic Disease Product Offered
    • 11.9.3 Merck KGaA Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2020-2022)
    • 11.9.4 Merck KGaA Main Business Overview
    • 11.9.5 Merck KGaA Latest Developments
  • 11.10 Teva Pharmaceuticals
    • 11.10.1 Teva Pharmaceuticals Company Information
    • 11.10.2 Teva Pharmaceuticals Gestational Trophoblastic Disease Product Offered
    • 11.10.3 Teva Pharmaceuticals Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2020-2022)
    • 11.10.4 Teva Pharmaceuticals Main Business Overview
    • 11.10.5 Teva Pharmaceuticals Latest Developments
  • 11.11 B.P Pharma
    • 11.11.1 B.P Pharma Company Information
    • 11.11.2 B.P Pharma Gestational Trophoblastic Disease Product Offered
    • 11.11.3 B.P Pharma Gestational Trophoblastic Disease Revenue, Gross Margin and Market Share (2020-2022)
    • 11.11.4 B.P Pharma Main Business Overview
    • 11.11.5 B.P Pharma Latest Developments

12 Research Findings and Conclusion

Summary:
Get latest Market Research Reports on Gestational Trophoblastic Disease. Industry analysis & Market Report on Gestational Trophoblastic Disease is a syndicated market report, published as Global Gestational Trophoblastic Disease Market Growth (Status and Outlook) 2022-2028. It is complete Research Study and Industry Analysis of Gestational Trophoblastic Disease market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

Last updated on

REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$3,660.00
$7,320.00
3,034.14
6,068.28
3,524.58
7,049.16
510,350.40
1,020,700.80
298,619.40
597,238.80
Credit card Logo

Related Reports


Reason to Buy

Request for Sample of this report